

## Practice Recommendations in the Diagnosis, Management, and Prevention of Carbon Monoxide Poisoning

Neil B. Hampson<sup>1</sup>, Claude A. Piantadosi<sup>2</sup>, Stephen R. Thom<sup>3</sup>, and Lindell K. Weaver<sup>4</sup>

<sup>1</sup>Virginia Mason Medical Center, Seattle, Washington; <sup>2</sup>Duke University Medical Center, Durham, North Carolina; <sup>3</sup>University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; and <sup>4</sup>Intermountain Medical Center, Salt Lake City, Utah

Carbon monoxide (CO) poisoning is common in modern society, resulting in significant morbidity and mortality in the United States annually. Over the past two decades, sufficient information has been published about carbon monoxide poisoning in the medical literature to draw firm conclusions about many aspects of the pathophysiology, diagnosis, and clinical management of the syndrome, along with evidence-based recommendations for optimal clinical practice. This article provides clinical practice guidance to the pulmonary and critical care community regarding the diagnosis, management, and prevention of acute CO poisoning. The article represents the consensus opinion of four recognized content experts in the field. Supporting data were drawn from the published, peer-reviewed literature on CO poisoning, placing emphasis on selecting studies that most closely mirror clinical practice.

**Keywords:** carbon monoxide poisoning; diagnosis; treatment; prevention

Carbon monoxide (CO) poisoning results in an estimated 50,000 emergency department visits in the United States annually (1) and is one of the leading causes of poisoning death. The last two decades have witnessed an enormous expansion of knowledge about clinical CO poisoning, much of it published in the peer-reviewed medical literature. That body of information is sufficient to draw firm conclusions about many aspects of the pathophysiology, diagnosis, and clinical management of the syndrome, along with construction of evidence-based recommendations for best clinical practice related to CO poisoning.

The four authors have published more than 100 papers on CO mechanisms, and the diagnosis and management of CO poisoning. In this article, they have collaborated to synthesize a state-of-the-art clinical practice approach to the CO-poisoned patient. This article represents a consensus of expert opinion. It is an evidence-based summary and not a meta-analysis or a comprehensive review of CO poisoning, but rather addresses the clinical issues that most frequently arise regarding CO poisoning.

In 1857, the physiologist Claude Bernard described the fact that CO produces hypoxia by binding with hemoglobin, reducing

the oxygen-carrying capacity of the blood and producing hypoxia in the tissues (2). CO also shifts the oxyhemoglobin curve to the left, which further reduces tissue PaO<sub>2</sub>. This hemoglobin mechanism is reversible because the binding of the CO molecule at the oxygen-carrying heme sites on hemoglobin is competitive with oxygen. The formation of carboxyhemoglobin (COHb) and the attendant tissue hypoxia were considered until fairly recently to be the major mechanism of CO toxicity. A number of scientific and clinical observations have indicated that additional mechanisms must be involved. For instance, the clinical presentation of the CO-poisoned patient has repeatedly been noted not to correlate with the blood COHb level (3, 4), and clinical improvement in the patient's condition does not correlate with clearance of the blood COHb level. Moreover, in canine studies, the toxicity of CO is greater when CO is administered by inhalation than by transfusion of CO-exposed red blood cells to the same COHb level (5), suggesting the importance of cellular toxicity caused by the cumulative effects of CO diffusing into the tissues, particularly during long exposures. Indeed, a low tissue PO<sub>2</sub> promotes cellular CO accumulation and CO binding to heme proteins.

It is now known that carbon monoxide poisoning causes both tissue hypoxia and direct cellular changes involving immunological or inflammatory damage by a variety of mechanisms (6–16). Some of these have been demonstrated only in animal models to date, whereas others have been confirmed in human studies. These mechanisms include the following:

- Binding to intracellular proteins (myoglobin, cytochrome *a*,<sub>3</sub>)
- NO generation → peroxynitrite production
- Lipid peroxidation by neutrophils
- Mitochondrial oxidative stress
- Apoptosis (programmed cell death)
- Immune-mediated injury
- Delayed inflammation

Indeed, some of these effects are related to interference with the normal signaling functions of endogenous CO, which is a physiological gas produced by enzymatic heme degradation (17) and is even being tested in preclinical and phase 1 studies as potential therapy in specific diseases (18). Most of the toxic mechanisms identified have been demonstrated to be modulated more favorably by hyperbaric than by normobaric oxygen. The contribution of each of these mechanisms of toxicity to clinical CO poisoning and in humans has not yet been determined. Although the use of CO as a therapeutic molecule is an exciting area, it is not the topic of this discussion of CO poisoning and its management. The interested reader is referred to the excellent review of the therapeutic CO field by Motterlini and Otterbein (18).

(Received in original form July 23, 2012; accepted in final form September 18, 2012)

*Author Contributions:* Each author was involved in drafting and revising the manuscript.

Correspondence and requests for reprints should be addressed to Neil B. Hampson, M.D., Department of Medicine, Virginia Mason Medical Center, H4-CHM, 1100 Ninth Avenue, Seattle, WA 98101. E-mail: neil.hampson@vmmc.org

CME will be available for this article at <http://ajrccm.atsjournals.org> or at <http://cme.atsjournals.org>

Am J Respir Crit Care Med Vol 186, Iss. 11, pp 1095–1101, Dec 1, 2012

Copyright © 2012 by the American Thoracic Society

Originally Published in Press as DOI: 10.1164/rccm.201207-1284CI on October 18, 2012

Internet address: [www.atsjournals.org](http://www.atsjournals.org)

## DIAGNOSIS

The diagnosis of CO poisoning is a clinical one: the common definition requires a history of recent CO exposure, the presence of symptoms consistent with CO poisoning, and demonstration of an elevated carboxyhemoglobin level (Figure 1).

Symptoms are required for diagnosis, but no single symptom is either sensitive or specific in CO poisoning. The most common symptoms in one series of 1,323 patients referred for treatment of CO poisoning in the United States included headache, dizziness, nausea/vomiting, confusion, fatigue, chest pain, shortness of breath, and loss of consciousness (19). A high index of suspicion is warranted, particularly during cold weather, in patients with acute coronary syndrome and arrhythmias. Failure to diagnose CO poisoning can have disastrous consequences for the patient and other members of an affected household. Despite the fact that some authors have long maintained that certain symptoms correlate closely with COHb levels, this is incorrect (19). There is no combination of symptoms that either confirms or excludes a diagnosis of CO poisoning. Although headache is the most common symptom, there is no characteristic headache pattern typical of CO poisoning (20).

For decades physicians have been taught to look for “cherry red” skin coloring in patients with CO poisoning, but this is rare (21, 22). The concept is that the color of blood changes when it is loaded with CO, as described by Hoppe in 1857 (23). Because carboxyhemoglobin is a brighter shade of red than oxyhemoglobin and the color of capillary blood contributes to skin color, it would seem reasonable that a poisoned patient’s appearance might change with sufficient amounts of circulating COHb. However, a lethal carboxyhemoglobin level is required for a human’s skin and mucous membranes to appear “cherry red.” Even when reflectance spectrophotometry is used to measure skin color of individuals dying of CO poisoning, less than one-half have “cherry red” skin (24).


The clinical diagnosis of acute CO poisoning should be confirmed by demonstrating an elevated carboxyhemoglobin level. COHb levels of at least 3–4% in nonsmokers and at least 10% in smokers can be considered outside the expected physiological range (25). The COHb level in smokers is generally in the 3–5% range (25). In the Second National Health and Nutrition Examination Survey (NHANES II), those who smoked one pack per day had COHb levels up to 5.6% (26). As a general rule, for each pack of cigarettes smoked per day, the COHb rises approximately 2.5% (27). Rarely, the COHb level in selected heavy

smokers, especially those with underlying lung pathology, can be more than 10% (28). COHb can be measured by laboratory spectrophotometry of blood obtained at the scene and transported with the patient to the hospital (29) or obtained at the time of emergency department evaluation. Laboratory spectrophotometry uses an instrument called a CO oximeter (or spectrophotometer) to measure the concentrations of the various hemoglobin species. This is done by transilluminating a specimen of blood with multiple wavelengths of light, measuring differential absorbance at the various wavelengths, and then calculating concentrations from the known absorption spectrum of each form of hemoglobin. Either arterial or venous blood may be used, as the COHb levels are similar (30, 31), provided the CO body stores are in near equilibrium with the CO partial pressure in the lungs. Under non-steady state conditions, venous COHb may be slightly above or below arterial COHb because of CO uptake or egress from tissues.

Confusion regarding arterial oxygenation and the presence of COHb may arise in two areas. First, many newer blood gas machines incorporate CO oximeters and perform spectrophotometry on injected blood, directly measuring the concentrations of oxy-, deoxy-, carboxy-, and methemoglobin. The arterial oxygen saturation ( $Sa_{O_2}$ ) reported with the blood gas results represents the amount of oxyhemoglobin present relative to the sum of all four hemoglobin species. This has not always been the case. Older blood gas machines contained algorithms for the calculation of oxygen saturation based on the oxyhemoglobin dissociation curve and effect of pH. An arterial blood specimen with pHa 7.40,  $Pa_{O_2}$  100 mm Hg, and  $Pa_{CO_2}$  40 mm Hg would be calculated from  $Pa_{O_2}$  and pHa to have an  $Sa_{O_2}$  of 97–98%. That result would be reported, irrespective of the amount of carboxyhemoglobin present. Thus, a patient with 40% COHb and  $Pa_{O_2}$  100 mm Hg would be reported to have an arterial oxygen saturation of 97–98%, when in reality 40% of the hemoglobin is bound with CO and the true fraction carrying oxygen would be 60% at maximum. This may remain an issue at a facility using a blood gas machine without a CO oximeter.

A second area of potential confusion relates to the fact that standard pulse oximeters using two wavelengths (660 and 990 nm) cannot differentiate carboxyhemoglobin (32). COHb and oxyhemoglobin ( $O_2Hb$ ) have similar absorbances (extinction coefficients) at 660 nm. This results in pulse oximeters measuring COHb similarly to  $O_2Hb$ . This was demonstrated in one series of 30 CO-poisoned patients with COHb at least 25% measured by CO oximeter and simultaneous pulse oximeter oxygen saturation ( $Sp_{O_2}$ ) greater than 90% in all (32). Because of differing extinction coefficients at 990 nm, COHb and  $O_2Hb$  are measured similarly but not identically. This becomes apparent only when COHb is greater than 40%. In a patient with COHb 50%, the  $Sa_{O_2}$  calculated from blood gas values is approximately 5% higher than the  $Sp_{O_2}$  value from a pulse oximeter (32).

Carboxyhemoglobin can also be measured at the scene by fingertip pulse CO oximetry (33, 34), a technology commercially available since 2005. The accuracy and reliability of the available pulse CO oximeter in the clinical setting have been questioned (35, 36) and also supported (37, 38). As such, if pulse CO oximetry is the basis for diagnosis, we recommend laboratory-based measurements by spectrophotometry for confirmation on arrival in the emergency department for patients being considered for hyperbaric oxygen therapy, until more experience has been gained with this technique. Because most hospitals do not have hyperbaric chambers, hyperbaric oxygen administration requires transfer, inconvenience, cost, and a small risk. As such, it would seem reasonable to confirm the pulse CO oximeter measurement by laboratory CO oximetry in that group. It is not



**Figure 1.** Triad required for diagnosis of acute carbon monoxide poisoning.

necessary to document an elevated COHb level in symptomatic persons who were in the same environment and exposed at the same time as someone with a documented COHb elevation. Because the COHb level serves only to confirm the diagnosis and does not predict either symptoms or outcome, measuring it in the simultaneously exposed, symptomatic individual does not change clinical management. In patients referred for suspected exposures to elevated environmental CO levels, COHb should be measured to document the exposure.

CO-poisoned patients are often discovered or present to the hospital emergency department with confusion or altered mental status. Whether or not there is a reliable exposure history, 100% normobaric oxygen should be administered to any person suspected of having CO poisoning while waiting for confirmation of the diagnosis by measurement of the COHb level (16).

In addition to considering a diagnosis based on the presenting symptoms and potentially an elevated COHb level, which could be low, or normal because of the interval from CO exposure to COHb measurement and oxygen treatment, information about the poisoning environment is important. Sometimes emergency or ambulance personnel measure ambient CO levels. These levels may be lower than at the time of actual CO exposure because of open doors or windows, but elevated ambient levels can confirm CO poisoning. It is important to discover the CO exposure source before discharging the patient, and for the source to be eliminated to prevent re-exposure.

**MANAGEMENT**

In all cases of CO poisoning, high-flow oxygen by mask or endotracheal tube is the front-line treatment (16). Oxygen accelerates the elimination of COHb and alleviates tissue hypoxia compared with air. It should be recognized, however, that no clinical trials have demonstrated superior efficacy of normobaric 100% oxygen over air (16). Increasing alveolar ventilation by adding CO<sub>2</sub> to O<sub>2</sub> for spontaneously breathing individuals was advocated to hasten COHb removal, based on observations dating to the 1920s (39). There are, however, marked individual differences in ventilatory responses, thus

making use of fixed CO<sub>2</sub>-O<sub>2</sub> mixtures unreliable and also risky because use may exacerbate acidosis in patients who are retaining CO<sub>2</sub> because of ventilatory depression from either severe CO poisoning or ingested drugs (40). Newer apparatus to increase ventilation while maintaining normocapnea has been described, but because CO pathophysiology is more complex than merely COHb-mediated hypoxia, applying such interventions may add complexity with limited benefits (41).

When hyperbaric oxygen is not available, it is reasonable to recommend the administration of 100% normobaric oxygen in the emergency department until COHb is normal (≤3%) and the patient's presenting symptoms of CO poisoning have resolved, usually for about 6 hours. The COHb is influenced by the fractional concentration of inhaled oxygen (F<sub>I</sub>O<sub>2</sub>) and falls more quickly as the F<sub>I</sub>O<sub>2</sub> increases. One hundred percent normobaric oxygen accelerates the dissolution of COHb, with an elimination half-life of approximately 74 minutes (42) compared with 320 minutes while breathing room air (43). For example, a poisoned patient with an initial COHb of 30% could have a relatively modest COHb level less than 10% if he breathed 100% normobaric oxygen for 2 hours. The F<sub>I</sub>O<sub>2</sub>, the duration of oxygen inhalation, and the interval from when the CO exposure stopped to when the COHb level was measured are therefore important. If the patient has been compliant with high-flow oxygen breathing for that approximately 6 hours and feels well, repeating the COHb level is not necessary.

Because of the relative inconvenience and cost of hyperbaric oxygen, a number of studies have tried to compare the efficacy of hyperbaric and normobaric oxygen in the treatment of CO poisoning (25, 44–50) (Table 1). Most of these studies have had significant methodological limitations that make drawing inferences about the efficacy of hyperbaric oxygen difficult (51–54). Problems have included such things as insignificant differences in the oxygen dose in the treatment arms (52), randomization to lengthy or impractical durations of normobaric oxygen administration (48), low rates of short-term follow-up (4–6 wk after poisoning and treatment) (48), clinically irrelevant outcome measures (42), and absence of any long-term follow-up (44–48,

**TABLE 1. SUMMARY OF STUDIES COMPARING NORMOBARIC WITH HYPERBARIC 100% OXYGEN FOR TREATMENT OF CARBON MONOXIDE POISONING**

Study (Ref. No.)	Year	Design	Intervention	Result	n
Raphael and colleagues (44)	1989	Randomized; if LOC, HBO <sub>2</sub> used	HBO <sub>2</sub> (2.0 ATA) vs. 6 h mask O <sub>2</sub> if no LOC; 1 HBO <sub>2</sub> vs. 2 HBO <sub>2</sub> if LOC	No difference in symptoms between groups at 1 mo	343
Ducasse and colleagues (45)	1995	Randomized, not blinded	HBO <sub>2</sub> (2.5 ATA) vs. mask O <sub>2</sub>	HBO <sub>2</sub> improved cerebral blood flow reactivity to acetazolamide	26
Thom and colleagues (46)	1995	Randomized, not blinded, excluded LOC	HBO <sub>2</sub> (2.9 ATA) vs. mask O <sub>2</sub>	No sequelae in HBO <sub>2</sub> vs. 23% for mask O <sub>2</sub> ; NNT = 4.3	65
Scheinkestel and colleagues (48)	1999	Double-blind RCT; cluster randomization; included LOC	3 to 6 HBO <sub>2</sub> (2.8 ATA) sessions vs. 3 d of mask O <sub>2</sub>	Very high number lost to 1 mo follow-up (54%), limiting any conclusion	191
Mathieu and colleagues (47)	1996	Randomized, not blinded, excluded LOC	HBO <sub>2</sub> vs. mask O <sub>2</sub>	Abstract only—HBO <sub>2</sub> reduced sequelae at 1 and 3 mo; none at 1 yr	575
Weaver and colleagues (49)	2002	Double-blind randomized, included LOC	3 HBO <sub>2</sub> (3 ATA for initial) in 24 h vs. 100% O <sub>2</sub> + 2 sham chamber sessions	Reduced cognitive sequelae (25 vs. 46%) at 6 wk (OR, 0.39; 95% CI, 0.2–0.78; P = 0.007); NNT = 4.8; with significant differences persisting to 12 mo	152
Annane and colleagues (50)	2011	Randomized, not blinded	Trial 1: HBO <sub>2</sub> session (2.0 ATA) + 4 h mask O <sub>2</sub> vs. 6 h mask O <sub>2</sub> if transient LOC Trial 2: 2 HBO <sub>2</sub> + 4 h mask O <sub>2</sub> vs. 1 HBO <sub>2</sub> + 4 h mask O <sub>2</sub> if initial coma	Outcomes measured by symptom questionnaire and physical examination at 1 mo. Trial 1—no difference in outcome as measured. Trial 2—“complete recovery” rate 47% with 2 HBO <sub>2</sub> vs. 68% with 1 HBO <sub>2</sub>	385

Definitions of abbreviations: ATA = atmosphere absolute; CI = confidence interval; HBO<sub>2</sub> = hyperbaric oxygen; LOC = loss of consciousness; NNT = number needed to treat; OR = odds ratio; RCT = randomized controlled trial.

50). The latter is especially important because it has been demonstrated that even individuals with significant structural brain injury on neuroimaging from CO poisoning can show long-term improvement in cognitive functioning impairment for 3 to 12 months postpoisoning (55).

Some authors have used a statistical meta-analysis from different trials and attempted to assign value to each study and then sum their discordant results for guidance. The American College of Emergency Physicians (ACEP) (53) and the Cochrane Review (54) both used this approach to the analysis of CO poisoning treatment and each concluded that additional, properly conducted trials would be desirable. Until such studies are available, patients must be treated on the basis of the information available. It is arguably as appropriate to select the existing study with the best design that most closely addresses the actual practical handling of these patients and use its findings to guide clinical practice. We believe that this study is that of Weaver and colleagues, published in 2002 (49), with supplemental information published in 2004 (56). In that study, CO-poisoned patients who received three hyperbaric oxygen treatments within 24 hours of presentation manifest approximately one-half the rate of cognitive sequelae at 6 weeks, 6 months, and 12 months after treatment as those who were treated with normobaric oxygen.

Hyperbaric oxygen should at least be considered in all cases of serious acute CO poisoning and normobaric 100% oxygen continued until the time of hyperbaric oxygen administration. Although risk factors for long-term cognitive impairment in patients not treated with hyperbaric oxygen have been identified, including age 36 years or more, exposure for at least 24 hours, loss of consciousness, and COHb at least 25%, no criterion is 100% predictive (3). In young patients in otherwise good health who have been experimentally exposed to CO for a short period of time, usually 2 hours or less, and with COHb levels less than 20%, acute measurable neurobehavioral effects are rarely manifested (57). However, a similar incidence of residual cognitive sequelae 6 weeks after CO poisoning has been reported in one group of patients with apparently milder poisoning compared with those with more severe poisoning (58). Thus, treatment decisions in the mildly poisoned patient are difficult and the subject of controversy, even among experts in the field. Pediatric CO poisoning can pose special challenges as inability to communicate can limit historical accounts, but in large series there appear to be no marked differences in manifestations versus those reported in adult populations (59–62).

Apolipoprotein E (APOE) is a 299-amino acid lipid-binding protein with three human isoforms:  $\epsilon 2$ ,  $\epsilon 3$ , and  $\epsilon 4$ . The  $\epsilon 4$  allele occurs in 14–25% of the population (63). APOE is involved in the distribution of cholesterol in the brain and neuritic growth and repair (64). APOE is up-regulated after neural injury (65). The presence of the  $\epsilon 4$  allele is associated with worse outcome after brain injury (66–68). Because the APOE genotype is associated with the degree of damage in various brain injury disorders, researchers characterized the APOE alleles in patients with CO poisoning treated with hyperbaric or normobaric oxygen in a randomized trial (49). They discovered an interaction between APOE genotype and the response to hyperbaric oxygen treatment in patients with acute CO poisoning (69). Those possessing the  $\epsilon 4$  allele may not derive benefit of treatment with hyperbaric oxygen, whereas those who do not have the  $\epsilon 4$  allele appear to have a reduction in the incidence of cognitive sequelae after hyperbaric oxygen therapy. Because most individuals in the general population do not carry the  $\epsilon 4$  allele, some recommend hyperbaric oxygen for all patients with acute CO poisoning, including those with milder poisoning (69).

Hyperbaric oxygen treatment may be precluded by such things as patient condition (70), logistical problems, and social issues,

among others. For example, patients with significant body burns in addition to CO poisoning from a fire may be at greater risk for mortality from their burns than CO poisoning. They should be managed in a specialized burn unit and cared for by a qualified burn surgeon. The decision regarding use of HBO<sub>2</sub> should be deferred to an experienced burn surgeon.

Other special populations, such as pregnant women and young children, are at risk for permanent sequelae of CO poisoning, and adult treatment criteria are generally applied to these patients. In pregnancy, fetal distress and fetal death are special concerns in CO poisoning, and HBO<sub>2</sub> has been administered safely to pregnant women, but there are no prospective studies of efficacy.

Because only about 3% of CO-poisoned patients who come to hospital-based medical management die and no study to date has clearly shown a reduction in mortality with hyperbaric versus normobaric oxygen therapy (71), the goal of hyperbaric treatment is the prevention of long-term and permanent neurocognitive dysfunction, not enhancement of short-term survival rates. Hyperbaric oxygen should not be withheld because a CO-poisoned individual is doing well clinically and appears not likely to die from the event (16).

The optimal dose and frequency of hyperbaric oxygen treatments for acute carbon monoxide poisoning remain unknown (51). As such, the protocol used and number of treatments administered are left to the discretion of the managing hyperbaric physician. In the study by Weaver and colleagues, noted previously, patients were treated at 3.0 atm abs during their first hyperbaric oxygen treatment (49). Of 1,165 patients treated from 2008 to 2011 and reported to a national surveillance system, 804 (69%) were also treated at 3.0 atm abs (72). It is reasonable to retreat persistently symptomatic patients to a maximum of three treatments, the number used for all patients in the 2002 study by Weaver and colleagues (49). Information for further guidance on treatment practices is available in the form of survey data gathered from U.S. hyperbaric treatment facilities (73).

If the CO exposure is believed to be intentional, toxicology screening should be considered to assess for toxic ingestions. In one study of 426 patients referred for treatment of intentional poisoning, 44% reported coingestion of other drugs or ethanol (74). Among patients with coingestions, 66% ingested ethanol. If a patient with intentional CO poisoning has mental status changes that seem disproportionate to his reported CO exposure, coingestion should be ruled out with measurement of a blood alcohol level, at a minimum.

Severe metabolic acidosis correlates with a high short-term mortality rate in CO-poisoned patients and, if the CO source was a house fire, is likely due to concomitant cyanide poisoning (71). That study demonstrated short-term mortality of 30–50% in CO-poisoned patients with initial pHa not exceeding 7.20, regardless of COHb levels. If arterial blood gas analysis demonstrates severe metabolic acidosis with pH less than 7.20 (71) or a plasma lactate level equal to or greater than 10 mmol/L (75) and the source of CO was a house fire, we believe that consideration should be given to empiric treatment for cyanide poisoning. A specific antidote is hydroxocobalamin, which has few side effects in individuals with smoke inhalation (75, 76). Smoke is a heterogeneous mixture of particulates, respiratory irritants, and systemic toxins. Each of these agents, along with heat, contributes to the pathological insult and treatment recommendations are beyond the scope of this article. Current treatment is based on supportive care and—not surprisingly—concomitant smoke inhalation with CO poisoning compounds health risks (77, 78).

All patients treated for acute accidental CO poisoning should be seen in clinical follow-up 1–2 months after the event. Although uncommon, late or evolving cognitive impairments including such

things as memory disturbance, depression, anxiety, inability to calculate, vestibular problems, and motor dysfunction can develop (16, 49, 79–82). These adverse sequelae can occur even after acute treatment of CO poisoning. If possible, a family member should accompany the patient to the follow-up appointment to provide their observations. Any person not believed to have recovered to baseline functioning by that time should be referred for formal neuropsychological evaluation, as well as symptom-directed evaluation and treatment. Individuals surviving an episode of accidental CO poisoning have an increased long-term mortality rate, as compared with the normal population (83). Causes of excess death (falls from heights, motor vehicle accidents, accidental drug overdose, etc.) suggest that residual brain injury may play a role. Patients with evidence of cardiac damage after poisoning should be referred for appropriate cardiology evaluation.

Persons surviving an episode of intentional CO poisoning are at extreme risk for premature death due to subsequent completion of suicide (83). All patients treated for intentional CO poisoning should have mandatory psychiatric follow-up. Family members should be made aware of this and recruited to assist in ensuring compliance.

**PREVENTION**

It is thought that public education programs designed to increase awareness of CO poisoning risks and the placement of warning labels on fuels or devices that emit large amounts of CO are effective at reducing the incidence of poisoning. When it was recognized in the early 1990s that many of those poisoned through indoor use of charcoal briquettes did not speak English (84), a nonverbal pictogram warning against indoor use was mandated on bags of charcoal briquettes starting in 1998 by the U.S. Consumer Product Safety Commission (CPSC). CPSC data show that from 1981 to 1997 there were approximately 25 CO deaths in the United States annually, due to charcoal briquettes. From 1998 to 2007, that number was reduced to approximately 10 deaths per year.

Planning effective educational programs and warning labels requires accurate knowledge of CO poisoning epidemiology. From 2008 to 2011, the U.S. Centers for Disease Control and Prevention teamed with the Undersea and Hyperbaric Medical Society (Durham, NC) to collect unidentified demographic and epidemiologic data on 1,912 CO-poisoned patients treated in the United States (85, 86). It is hoped that the insights gained

will lead to enhanced effectiveness for public education programs and poisoning prevention.

As an example, CO poisoning has been shown to be especially common during storm-related power outages, when people turn to the indoor use of charcoal briquettes for cooking and heating, improper use of gasoline-powered electrical generators to provide electricity, and indoor use of gasoline-powered pressure washers to clean up (87). Sufficient data are available to predict the predominant sources of CO depending on geography and type of storm, as well as the window of opportunity for intervention after the storm strikes. Broadcasting public service warnings, multilingual in some cases, offers the potential for significant poisoning prevention.

Significant opportunities exist to prevent CO poisoning through the use of CO alarms (88, 89). The U.S. Centers for Disease Control and Prevention recommend a CO alarm in every residence (90). They should be installed in the hallway outside sleeping areas (91). Even though CO is slightly lighter than the mixture of nitrogen and oxygen comprising air, CO alarms can be installed at any height because the gas diffuses rapidly throughout an enclosed space (92).

Legislation mandating the installation of residential CO alarms, in addition to smoke alarms already present, has been enacted by numerous states and is currently being considered by many others (93). The state laws differ mainly regarding whether homes without fuel-burning appliances or attached garages are exempted from required CO alarm installation. It is our opinion that they should not be exempted because a large proportion of patients treated for severe CO poisoning in the United States are exposed from CO-emitting devices (e.g., charcoal grills, gasoline-powered electrical generators) that are brought indoors or otherwise improperly operated (73).

One publication has emphasized that proper operation of residential CO alarms themselves is equally important (94). Among a sampling of 30 CO alarms in current residential use, 12 (40%) were older than 10 years. Of these, 8 (75%) malfunctioned when tested. Depending on the make and model, CO alarms require replacement at either 5 or 7 years after installation. Many newer models alert the consumer when replacement is necessary.

**CONCLUSIONS**

An enormous body of information about carbon monoxide poisoning has been developed in the past two decades. Most accidental

**TABLE 2. KEY MESSAGES ON CARBON MONOXIDE POISONING**

---

I. Basic pathophysiology: Several mechanisms of CO toxicity exist, in addition to hypoxemia from carboxyhemoglobin (COHb) formation

II. Diagnosis

- a. Symptoms: Nonspecific. Most common are headache, dizziness, nausea/vomiting, confusion, fatigue, chest pain, shortness of breath, and loss of consciousness
- b. Signs: Cherry red discoloration is rare
- c. Role of carboxyhemoglobin level: Confirms clinical diagnosis. Correlates poorly with symptoms or prognosis
- d. Prediagnosis management: Administer 100% oxygen while waiting for COHb level

III. Management

- a. Normobaric oxygen therapy: If chosen for treatment, 100% oxygen by nonrebreather facemask or endotracheal tube until COHb normal (<3%) and patient asymptomatic (typically 6 h)
- b. Selection for hyperbaric oxygen (HBO<sub>2</sub>) therapy: Currently not completely clarified. Poisoned patients with loss of consciousness, ischemic cardiac changes, neurological deficits, significant metabolic acidosis, or COHb > 25% warrant HBO<sub>2</sub>. More mildly poisoned patients may be treated at the discretion of the managing physician (see text)
- c. Goals of HBO<sub>2</sub> therapy: Prevent neurocognitive sequelae
- d. Optimal HBO<sub>2</sub> protocol: Unknown. Recommend retreatment of persistently symptomatic patients to a maximum of 3 treatments
- e. Intentional poisonings: Coingestion of other toxins common. Consider toxicological screening
- f. Concomitant cyanide poisoning: Suspect if CO source is house fire. Consider empiric treatment if pHa < 7.20 or plasma lactate > 10 mmol/L

IV. Patient follow-up

- a. Accidental poisoning: Follow-up in 4–6 wk to screen for cognitive sequelae
- b. Intentional poisoning: Psychiatric follow-up mandatory in light of high rate of subsequent completed suicide

V. Prevention

- a. Public education: Educate about proper generator use and risk from combustion of fuels indoors
- b. CO alarms: Encourage minimum of 1 per home, located near sleeping area. Replace alarms every 5–7 yr, as per manufacturer’s instructions

---

CO poisoning should be preventable. However, when it is not prevented, these guidelines offer clear recommendations regarding optimal clinical practice, based on current information on the diagnosis and management of patients with CO poisoning (Table 2).

**Author disclosures** are available with the text of this article at [www.atsjournals.org](http://www.atsjournals.org).

## References

- Hampson NB, Weaver LK. Carbon monoxide poisoning: a new incidence for an old disease. *Undersea Hyperb Med* 2007;34:163–168.
- Bernard C. Leçons sur les effets des substances toxiques et médicamenteuses. Paris: Ballière; 1857.
- Weaver LK, Valentine KJ, Hopkins RO. Carbon monoxide poisoning: risk factors for cognitive sequelae and the role of hyperbaric oxygen. *Am J Respir Crit Care Med* 2007;176:491–497.
- Hampson NB, Hauff NM. Carboxyhemoglobin levels in carbon monoxide poisoning: do they correlate with the clinical picture? *Am J Emerg Med* 2008;26:665–669.
- Goldbaum LR, Orellano T, Dergal E. Mechanism of the toxic action of carbon monoxide. *Ann Clin Lab Sci* 1976;6:372–376.
- Brown SD, Piantadosi CA. Reversal of carbon monoxide–cytochrome *c* oxidase binding by hyperbaric oxygen *in vivo*. *Adv Exp Med Biol* 1989;248:747–754.
- Brown SD, Piantadosi CA. *In vivo* binding of carbon monoxide to cytochrome *c* oxidase in rat brain. *J Appl Physiol* 1990;68:604–610.
- Brown SD, Piantadosi CA. Recovery of energy metabolism in rat brain after carbon monoxide hypoxia. *J Clin Invest* 1992;89:666–672.
- Piantadosi CA, Zhang J, Levin ED, Folz RJ, Schmechel DE. Apoptosis and delayed neuronal damage after carbon monoxide poisoning in the rat. *Exp Neurol* 1997;147:103–114.
- Thom SR. Antagonism of carbon monoxide–mediated brain lipid peroxidation by hyperbaric oxygen. *Toxicol Appl Pharmacol* 1990;105:340–344.
- Thom SR, Bhopale VM, Fisher D, Zhang J, Gimotty P. Delayed neuropathology after carbon monoxide poisoning is immune-mediated. *Proc Natl Acad Sci USA* 2004;101:13660–13665.
- Thom SR, Bhopale VM, Fisher D. Hyperbaric oxygen reduces delayed immune-mediated neuropathology in experimental carbon monoxide toxicity. *Toxicol Appl Pharmacol* 2006;213:152–159.
- Thom SR, Bhopale VM, Han ST, Clark JM, Hardy KR. Intravascular neutrophil activation due to carbon monoxide poisoning. *Am J Respir Crit Care Med* 2006;74:1239–1248.
- Thom SR. Carbon monoxide pathophysiology and treatment. In: Neuman TS, Thom SR, editors. *Physiology and medicine of hyperbaric oxygen therapy*. Philadelphia: Saunders Elsevier; 2008. pp. 321–347.
- Thom SR, Bhopale VM, Milovanova TM, Hardy KR, Logue CJ, Lambert DS, Troxel AB, Ballard K, Eisinger D. Plasma biomarkers in carbon monoxide poisoning. *Clin Toxicol (Phila)* 2010;48:47–56.
- Weaver LK. Clinical practice: carbon monoxide poisoning. *N Engl J Med* 2009;369:1217–1225.
- Coburn RF. Endogenous carbon monoxide metabolism. *Annu Rev Med* 1973;24:241–250.
- Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. *Nat Rev Drug Discov* 2010;9:728–743.
- Hampson NB, Dunn SL; members of the UHMS/CDC CO Poisoning Surveillance Group. Symptoms of acute carbon monoxide poisoning do not correlate with the initial carboxyhemoglobin level. *Undersea Hyperb Med* 2012;39:657–665.
- Hampson NB, Hampson LA. Characteristics of the headache associated with acute carbon monoxide poisoning. *Headache* 2002;42:220–223.
- Simini B. Cherry-red discoloration in carbon monoxide poisoning. *Lancet* 1988;352:1154.
- Gorman DF, Clayton D, Gilligan JE, Webb RK. A longitudinal study of 100 consecutive admissions for carbon monoxide poisoning to the Royal Adelaide Hospital. *Anaesth Intensive Care* 1992;20:311–316.
- Hoppe F. Über die Einwirkung des Kohlenoxydgases auf das Hämatoglobulin. *Virchows Arch Pathol Anat Physiol Klin Med* 1857;11:288.
- Findlay GH. Carbon monoxide poisoning: optics and histology of skin and blood. *Br J Dermatol* 1988;119:45–51.
- Radford EP, Drizd TA. Blood carbon monoxide levels in persons 3–74 years of age: United States, 1976–80. Advance data from Vital and Health Statistics, No. 76. DHHS Publ. No. (PHS) 82-1250. Hyattsville, MD: National Center for Health Statistics; Office of Health Research, Statistics, and Technology; Public Health Service; U.S. Department of Health and Human Services; 1982.
- Istvan JA, Cunningham TW. Smoking rate, carboxyhemoglobin, and body mass in the Second National Health and Nutrition Examination Survey (NHANES II). *J Behav Med* 1992;15:559–572.
- Aker J. Carboxyhemoglobin levels in banked blood: a comparison of cigarette smokers and nonsmokers. *AANA J* 1987;55:421–426.
- Sen S, Peltz C, Beard J, Zeno B. Recurrent carbon monoxide poisoning from cigarette smoking. *Am J Med Sci* 2010;340:427–428.
- Hampson NB. Stability of carboxyhemoglobin in stored and mailed blood samples. *Am J Emerg Med* 2008;26:191–195.
- Lopez DM, Weingarten-Arams JS, Singer LP, Conway EE. Relationship between arterial, mixed venous, and internal jugular carboxyhemoglobin concentrations at low, medium, and high concentrations in a piglet model of carbon monoxide toxicity. *Crit Care Med* 2000;28:1998–2001.
- Touger M, Gallagher EJ, Tyrell J. Relationship between venous and arterial carboxyhemoglobin levels in patients with suspected carbon monoxide poisoning. *Ann Emerg Med* 1995;25:481–483.
- Hampson NB. Pulse oximetry in severe carbon monoxide poisoning. *Chest* 1998;114:1036–1041.
- Barker SJ, Curry J, Redford D, Morgan S. Measurement of carboxyhemoglobin and methemoglobin by pulse oximetry: a human volunteer study. *Anesthesiology* 2006;105:892–897.
- Hampson NB, Weaver LK. Noninvasive CO measurement by first responders: a suggested management algorithm. *J Emerg Med Serv JEMS* 2006;24:10–12.
- Touger M, Birnbaum A, Wang J, Chou K, Pearson D, Bijur P. Performance of the RAD-57 pulse CO-oximeter compared with standard laboratory carboxyhemoglobin measurement. *Ann Emerg Med* 2010;56:382–388.
- Weaver LK, Churchill SK, Deru K, Cooney D. False positive rate of carbon monoxide saturation by pulse oximetry of emergency department patients. *Respir Care* (In press)
- Piatkowski A, Ulrich D, Grieb G, Pallua N. A new tool for the early diagnosis of carbon monoxide intoxication. *Inhal Toxicol* 2009;21:1144–1147.
- Roth D, Herkner H, Schreiber W, Hubmann N, Gamper G, Laggner AN, Havel C. Accuracy of noninvasive multiwave pulse oximetry compared with carboxyhemoglobin from blood gas analysis in unselected emergency department patients. *Ann Emerg Med* 2011;58:74–79.
- Henderson Y, Haggard HW. The elimination of carbon monoxide from the blood after a dangerous degree of asphyxiation, and a therapy for accelerating the elimination. *J Pharmacol Exp Ther* 1920;16:11–20.
- Donald KW, Paton WDM. Gases administered in artificial respiration; with particular reference to the use of carbon dioxide. *BMJ* 1955;1:313–318.
- Fisher JA, Iscoe S, Fedorko L, Duffin J. Rapid elimination of CO through the lungs: coming full circle 100 years on. *Exp Physiol* 2011;96:1262–1269.
- Weaver LK, Howe S, Hopkins RO, Chan K. Carboxyhemoglobin half-life in carbon monoxide poisoned patients treated with 100% oxygen at atmospheric pressure. *Chest* 2000;117:801–808.
- Peterson JE, Stewart RD. Absorption and elimination of carbon monoxide by inactive young men. *Arch Environ Health* 1970;21:165–171.
- Raphael JC, Elkharrat D, Jars-Guinestre MC, Chastang C, Chasles V, Vercken JB, Gajdos P. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. *Lancet* 1989;2:414–419.
- Ducasse JL, Celsis P, Marc-Vergnes JP. Non-comatose patients with acute carbon monoxide poisoning: hyperbaric or normobaric oxygenation? *Undersea Hyperb Med* 1995;22:9–15.
- Thom SR, Taber RL, Mediguren II, Clark JM, Hardy KR, Fisher AB. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention with hyperbaric oxygen. *Ann Emerg Med* 1995;25:474–480.
- Mathieu D, Wattel F, Mathieu-Nolf M, Tempe JF, Bouachour G, Sainty JM. Randomized prospective study comparing the effect of HBO<sub>2</sub> versus 12 hours of NBO in non comatose CO poisoned patients: results of the interim analysis [abstract]. *Undersea Hyperb Med* 1996;23:7–8.
- Scheinkestel CD, Bailey M, Myles PS, Jones K, Cooper DJ, Millar IL, Tuxen DV. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide poisoning: a randomized controlled clinical trial. *Med J Aust* 1999;170:203–210.

49. Weaver LK, Hopkins RO, Chan KJ, Churchill S, Elliott CG, Clemmer TP, Orme JF Jr, Thomas FO, Morris AH. Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J Med* 2002;347:1057–1067.
50. Annane D, Chadda K, Gajdos P, Jars-Guincestre MC, Chevret S, Raphael JC. Hyperbaric oxygen for acute domestic carbon monoxide poisoning: two randomized controlled trials. *Intensive Care Med* 2011;37:486–492.
51. Hampson NB, Mathieu D, Piantadosi CA, Thom SR, Weaver L. Carbon monoxide poisoning: Interpretation of randomized clinical trials and unresolved treatment issues. *Undersea Hyperb Med* 2001;28:157–164.
52. Hampson NB. Acute carbon monoxide poisoning and the role of hyperbaric oxygen. *Emerg Med Australas* 2004;16:481.
53. Wolf FJ, Lavonas EJ, Sloan EP, Jagoda AS. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. *Ann Emerg Med* 2008;51:138–152.
54. Buckley NA, Juurlick DN, Isbister G, Bennett MH, Lavonas EJ. Hyperbaric oxygen for carbon monoxide poisoning. *Cochrane Database Syst Rev* [serial on the Internet]. 2011 [accessed October 2012];4: CD002041. Available from: <http://summaries.cochrane.org/>
55. Hsiao CL, Kuo HC, Huang CC. Delayed encephalopathy after carbon monoxide intoxication—long-term prognosis and correlation of clinical manifestations and neuroimages. *Acta Neurol Taiwan* 2004;13:64–70.
56. Weaver LK, Hopkins RO, Chan KJ, Thomas F, Churchill SK, Elliott CG, Morris A; Carbon Monoxide Research Group. LDS Hospital, Utah in response to Scheinkestel *et al.* and Emerson: the role of hyperbaric oxygen in carbon monoxide poisoning. *Emerg Med Australas* 2004;16:394–399, discussion 481–482.
57. Raub JA, Benignus BA. Carbon monoxide and the nervous system. *Neurosci Biobehav Rev* 2002;26:925–940.
58. Chambers CA, Hopkins RO, Weaver LK, Key C. Cognitive and affective outcomes of more severe compared to less severe carbon monoxide poisoning. *Brain Inj* 2008;22:387–395.
59. Piatt JP, Kaplan AM, Bond GR, Berg RA. Occult carbon monoxide poisoning in an infant. *Pediatr Emerg Care* 1990;6:21–23.
60. Foster M, Goodwin SR, Williams C, Loeffler J. Recurrent acute life-threatening events and lactic acidosis caused by chronic carbon monoxide poisoning in an infant. *Pediatrics* 1999;104:e34.
61. Klasner AE, Smith SR, Thompson MW, Scalzo AJ. Carbon monoxide mass exposure in a pediatric population. *Acad Emerg Med* 1998;5: 992–996.
62. Hampson NB, Norkool DM. Carbon monoxide poisoning in children riding in the back of pickup trucks. *JAMA* 1992;267:538–540.
63. Tsugang D, Kukull W, Sheppard L, Barnhart RL, Pesking E, Edland SD, Schellenberg G, Raskind M, Larson EB. Impact of a sample selection on APOE  $\epsilon 4$  allele frequency: a comparison of two Alzheimer's disease samples. *J Am Geriatr Soc* 1996;44:704–707.
64. Ignatius MJ, Gebicke-Harter PJ, Skene JH, Schilling JW, Weisgraber KH, Mahley RW, Shooter EM. Expression of apolipoprotein E during nerve degeneration and regeneration. *Proc Natl Acad Sci USA* 1986;83:1125–1129.
65. Amar S, Saada A, Rotshenker S. Lesion-induced changes in the production of newly synthesized and secreted apo-E and other molecules are independent of the concomitant recruitment of blood-borne macrophages into injury peripheral nerves. *J Neurochem* 1992;59: 1287–1292.
66. Friedman G, Fromm P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, Babaey S, Yehuda B, Groswasser Z. Apolipoprotein E- $\epsilon 4$  genotype predicts a poor outcome in survivors of traumatic brain injury. *Neurology* 1999;52:244–248.
67. McCarron MO, Weir CJ, Muir KW, Hoffman KL, Graffagnino C, Nicoll JA, Lees KR, Alberts MJ. Effect of apolipoprotein E genotype on in-hospital mortality following intracerebral haemorrhage. *Acta Neurol Scand* 2003;107:106–109.
68. Grocott HP, Newman MF, El-Moalem H, Bainbridge D, Butler A, Laskowitz DT. Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 2001;122:622–623.
69. Hopkins RO, Weaver LK, Valentine KJ, Mower C, Churchill S, Carlquist J. Apolipoprotein E genotype and response of carbon monoxide poisoning to hyperbaric oxygen treatment. *Am J Respir Crit Care Med* 2007;176:1001–1006.
70. Hampson NB, Zmaeff JL. Outcome of patients experiencing cardiac arrest with carbon monoxide poisoning and treated with hyperbaric oxygen. *Ann Emerg Med* 2001;38:36–41.
71. Hampson NB, Hauff NM. Risk factors for short-term mortality from carbon monoxide poisoning treated with hyperbaric oxygen. *Crit Care Med* 2008;36:2523–2527.
72. Hampson NB, Dunn SL, Yip SY, Clower JH, Weaver LK. The UHMS/CDC carbon monoxide poisoning surveillance program: three-year data. *Undersea Hyperb Med* 2012;39:667–685.
73. Hampson NB, Little CE. Hyperbaric treatment of patients with carbon monoxide poisoning in the United States. *Undersea Hyperb Med* 2005; 32:21–26.
74. Hampson NB, Bodwin D. Frequency of toxic co-ingestions in intentional carbon monoxide poisoning. *J Emerg Med* (In press)
75. Baud FJ. Cyanide: critical issues in diagnosis and treatment. *Hum Exp Toxicol* 2007;26:191–291.
76. Lawson-Smith P, Jansen EC, Hyldegaard O. Cyanide intoxication as part of smoke inhalation: a review on diagnosis and treatment from the emergency perspective. *Scand J Traum Resusc Emerg Med* 2011; 19:14.
77. Chou KJ, Fisher JL, Silver EJ. Characteristics and outcome of children with carbon monoxide poisoning with and without smoke exposure referred for hyperbaric oxygen therapy. *Pediatr Emerg Care* 2000;16: 151–155.
78. Toon MH, Maybauer MO, Greenwood JE, Maybauer DM, Fraser JF. Management of acute smoke inhalation injury. *Crit Care Resusc* 2010; 12:53–61.
79. Smith JS, Brandon S. Morbidity from carbon monoxide poisoning at three-year follow-up. *BMJ* 1973;1:318–321.
80. Mimura K, Harada M, Sumiyoshi S, Tohya G, Takagi M, Fujita E, Takata A, Tatetsu S. Long-term follow-up study on sequelae of carbon monoxide poisoning: serial investigation 33 years after poisoning. *Seishin Shinkeigaku Zasshi* 1999;101:592–618.
81. Hopkins RO, Weaver LK. Cognitive outcomes 6 years after acute carbon monoxide poisoning [abstract]. *Undersea Hyperb Med* 2008;35: 258.
82. Weaver LK, Hopkins RO, Churchill SK, Deru K. Neurological outcomes 6 years after acute carbon monoxide poisoning [abstract]. *Undersea Hyperb Med* 2008;35:258–259.
83. Hampson NB, Hauff NM, Rudd RA. Increased long-term mortality among survivors of acute carbon monoxide poisoning. *Crit Care Med* 2009;37:1941–1947.
84. Hampson NB, Kramer CC, Dunford RG, Norkool DM. Accidental carbon monoxide poisoning resulting from indoor burning of charcoal briquets. *JAMA* 1994;271:52–53.
85. Clower JH, Hampson NB, Iqbal S, Yip FY. Recipients of hyperbaric oxygen therapy for carbon monoxide poisoning and exposure circumstances. *Am J Emerg Med* 2012;30:846–851.
86. Hampson NB, Bell J, Clower JH, Dunn SL, Weaver LK. Partnering with a medical society to perform online disease surveillance. *Undersea Hyperb Med* 2012;39:647–655.
87. Hampson NB, Stock AL. Storm-related carbon monoxide poisoning: lessons learned from recent epidemics. *Undersea Hyperb Med* 2006; 33:257–263.
88. Weaver LK, Deru K. Carbon monoxide poisoning at hotels, motels, and resorts. *Am J Prev Med* 2007;33:23–27.
89. Hampson NB, Weaver LK. Residential carbon monoxide alarm use: opportunities for poisoning prevention. *J Environ Health* 2011;73:30–33.
90. Centers for Disease Control and Prevention. Carbon monoxide poisoning: prevention guidance. Available from: <http://www.cdc.gov/co/guidelines.htm>
91. US Consumer Product Safety Commission. Change clocks, change batteries; dead batteries can lead to death. Available from: <http://www.cpsc.gov/cpscpub/prerel/prhtml12/12027.html>
92. Hampson NB, Courtney TG, Holm JR. Should the placement of carbon monoxide (CO) detectors be influenced by CO's weight relative to air? *J Emerg Med* 2012;42:478–482.
93. First Alert. Fire safety legislation. Available from: <http://www.firstalert.com/legislation-map/>
94. Ryan TJ, Arnold KJ. Residential carbon monoxide detector failure rate in the United States. *Am J Public Health* 2011;101:e15–e17.